Experience with a provocative test of calcitonin release as a prospective screening for preclinical medullary thyroid carcinoma in MEN type 2A family members.
We report our experience with a provocative test of calcitonin (CT) release using a combined stimulus of intravenous 10% CaCl2 solution and pentagastrin on 34 normal adults (15 females: age 41 +/- 12.3 years and range 22-65 years; and 19 males: age 43 +/- 9.1 years and range 23-60 years) and in 44 family members of three proven multiple endocrine neoplasia type 2A syndrome (MEN 2A) patients. A commercial radioimmunoassay was used to determine the serum CT levels. Peak CT levels were reached within 2 to 5 minutes after administration of the stimulus in all subjects tested. In the group of normal subjects there was no significant difference in the mean basal CT levels between males (54.8 +/- 21.7 pg/ml) and females (56.5 +/- 34.8 pg/ml), whilst the mean peak response values for males was 146.3 +/- 120.6 pg/ml, which was significantly different from the mean value of females, namely 71.6 +/- 39.0 pg/ml. We did not find significant correlations between the basal CT level, peak CT response, and age. Of the 44 family members tested, 9 showed an exaggerated CT response to the combined stimulus and subsequently had a total thyroidectomy. Histological examination confirmed C-cell hyperplasia (CCH) in one and medullary thyroid carcinoma (MTC) in the other 8. Three of the 9 had high basal plasma CT levels. The 9 patients were retested postoperatively and all showed a flat response to the combined stimulus. Those family members with histological proof of MTC or CCH were screened for genetic linkage to the disease gene for MEN 2A using probe MCK2, and showed correlation in each instance.(ABSTRACT TRUNCATED AT 250 WORDS)
van Lathem
J J
JJ
Department of Chemical Pathology, University of the Orange Free State, Bloemfontein, Republic of South Africa.
Vermaak
W J
WJ
Kuyl
J M
JM
Mollentze
W
W
Jansen
S
S
Wolmarans
L
L
Pelser
H
H
Barry
R
R
Kruger
A J
AJ
Wolfaardt
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers; D002116:Calcitonin / Q000097:blood / Q000378:metabolism*; D002122:Calcium Chloride / Q000008:administration & dosage; D002648:Child; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000175:diagnosis* / Q000235:genetics / Q000503:physiopathology; D010375:Pedigree; D010418:Pentagastrin / Q000008:administration & dosage; D011230:Precancerous Conditions / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology; D011863:Radioimmunoassay; D013961:Thyroid Gland / Q000473:pathology; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000503:physiopathology
D015415:Biomarkers; D002116:Calcitonin; D010418:Pentagastrin; D002122:Calcium Chloride